Purple Biotech (PPBT) — Cash Flow-to-Debt Ratio
Purple Biotech (PPBT) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of $-1.04 Million could theoretically repay 0% of its total liabilities ($7.91 Million) in one year. See PPBT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Purple Biotech Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Purple Biotech across 13 annual periods. Also explore Purple Biotech (PPBT) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Purple Biotech (2013–2025)
Year-by-year debt coverage analysis for Purple Biotech. For market capitalisation and broader financial context, see market cap of Purple Biotech.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-5.54 Million | $7.91 Million | ▲ +79.9% |
| 2024 | -3.48x | $-14.37 Million | $4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | $-19.93 Million | $10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | $-16.73 Million | $7.52 Million | ▲ +24.9% |
| 2021 | -2.96x | $-15.07 Million | $5.09 Million | ▲ +0.8% |
| 2020 | -2.98x | $-12.09 Million | $4.05 Million | ▼ -106.3% |
| 2019 | -1.45x | $-5.58 Million | $3.86 Million | ▲ +36.5% |
| 2018 | -2.28x | $-8.48 Million | $3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | $-8.63 Million | $5.59 Million | ▲ +62.3% |
| 2016 | -4.10x | $-6.26 Million | $1.53 Million | ▼ -71.2% |
| 2015 | -2.39x | $-3.31 Million | $1.38 Million | ▲ +47.9% |
| 2014 | -4.59x | $-4.53 Million | $986.00K | ▼ -1026.9% |
| 2013 | -0.41x | $-512.00K | $1.26 Million | — |